The "Beinao-1," a semi-invasive brain-computer interface (BCI) developed by ZGC Development Group-invested Beijing Xinzhida Neural Technology Co., Ltd. (Xinzhida), is set for clinical implantation. This upcoming surgery marks the device's sixth human implantation.

Luo Minmin, director of Chinese Institute for Brain Science (“CIBR”) and founder of Xinzhida, revealed that the registered clinical product of "Beinao-1" has entered the production stage, with a plan to start registered clinical trials in the middle of 2026. The research and development of the high-performance invasive intelligent brain-computer system— "Beinao-2"— is also progressing steadily and is expected to enter the clinical verification stage in 2026.

In 2022, ZGC Development Group established the “Beinao Fund” to support CIBR, an institute focusing on the R&D and clinical application of brain-computer interfaces. The Fund aims to connect key links in the upstream and downstream of the BCI industry. The fund has partnered with Professor Luo Minmin to initiate and establish the Brain-Computer Interface Integration Technology Center - Xinzhida. As the executor Beijing's "Brain-Computer System Enhancement Plan", Xinzhida mainly carries out R&D and industrialization of BCI technologies.

Since February 2025, CIBR and Xinzhida, in collaboration with Peking University First Hospital, Xuanwu Hospital, and Beijing Tiantan Hospital, have successfully carried out five cases of human implantation of the "Beinao-1" intelligent brain-computer system. They have also achieved the world's first Chinese speech decoding for fully-implanted semi-invasive wireless brain-computer interfaces.